- Home
- NFE vs VKTX Comparison
NFE vs VKTX Comparison
Compare NFE & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFE
- VKTX
- Stock Information
- Founded
- NFE 2014
- VKTX 2012
- Country
- NFE United States
- VKTX United States
- Employees
- NFE N/A
- VKTX N/A
- Industry
- NFE Oil/Gas Transmission
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- NFE Utilities
- VKTX Health Care
- Exchange
- NFE Nasdaq
- VKTX Nasdaq
- Market Cap
- NFE 3.2B
- VKTX 3.4B
- IPO Year
- NFE 2019
- VKTX 2015
- Fundamental
- Price
- NFE $8.80
- VKTX $25.65
- Analyst Decision
- NFE Buy
- VKTX Strong Buy
- Analyst Count
- NFE 5
- VKTX 11
- Target Price
- NFE $17.60
- VKTX $95.18
- AVG Volume (30 Days)
- NFE 7.3M
- VKTX 4.0M
- Earning Date
- NFE 03-03-2025
- VKTX 04-23-2025
- Dividend Yield
- NFE 2.26%
- VKTX N/A
- EPS Growth
- NFE N/A
- VKTX N/A
- EPS
- NFE N/A
- VKTX N/A
- Revenue
- NFE $2,354,111,000.00
- VKTX N/A
- Revenue This Year
- NFE $23.61
- VKTX N/A
- Revenue Next Year
- NFE $22.65
- VKTX N/A
- P/E Ratio
- NFE N/A
- VKTX N/A
- Revenue Growth
- NFE N/A
- VKTX N/A
- 52 Week Low
- NFE $7.58
- VKTX $24.41
- 52 Week High
- NFE $30.80
- VKTX $82.00
- Technical
- Relative Strength Index (RSI)
- NFE 39.27
- VKTX 37.65
- Support Level
- NFE $7.58
- VKTX $25.80
- Resistance Level
- NFE $12.59
- VKTX $29.60
- Average True Range (ATR)
- NFE 0.85
- VKTX 1.69
- MACD
- NFE 0.10
- VKTX -0.17
- Stochastic Oscillator
- NFE 27.35
- VKTX 17.19
About NFE New Fortress Energy Inc.
New Fortress Energy is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to both lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include terminals and infrastructure, or T&I, and ships.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.